Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist

Psychopharmacology

Volumn 137, Issue 3, 1998, Pages 223-232

  Wetzel, H ^a   Grunder G ^a   Hillert, A ^a   Philipp, M ^a   Gattaz, W F ^b   Sauer, H ^c   Adler, G ^b   Schroder J ^d   Rein, W ^e   Benkert, O ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Ctrl Institute of Mental Health   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SANOFI   (France)

Author keywords

Amisulpride; Antipsychotic efficacy; Atypical neuroleptic; Dopamine; Extrapyramidal tolerability; Flupentixol; Mixed D1 D2 like antagonism; Schizophrenia; Selective D2 like antagonism

Indexed keywords

AMISULPRIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPENTIXOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUPENTHIXOL; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE; TREATMENT OUTCOME;

EID: 7144235791     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050614     Document Type: Article

References (47)

1. Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 338:162-168
2. Andreasen NC (1983a) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City
3. Andreasen NC (1983b) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City
4. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
5. Bauer P (1991) Multiple testing in clinical trials. Stat Med 10:871-890
6. Bech P (1981) Rating scales for affective disorders: their validity and consistency. Avta Psychiatr Scand [Suppl 295]:64
7. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72
8. 1 selective benzophthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102
9. Clinical Global Impressions (1976) In: Guy W (ed) ECDEU assessment manual for psychopharmacology (Rev. Ed.). US Dept of Health, Education and Welfare. Publication No (ADM) 76 338. Rockville, Md., pp 217-222
10. Coche BA, Chopin MJ (1986) Place de l'amisulpride dans le groupe des benzamides substitués. Actualités Psychiatriques9: 172-177
11. 1 receptors. J Pharmacol Exp Ther 249:769-774
12. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
13. 1 antagonist SCH 39166 in six cases of acute psychotic states Psychopharmacology 121: 323-327
14. 1 DA receptor antagonist SCH 39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121:317-322
15. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990) Amisulpiride versus haloperidol in treatment of schizophrenic patients. Results of a double-blind study. Pharmacopsychiatry 23:125-130
16. Dufour A, Desanti C (1988) Pharmacocinétique et métabolisme de l'amisulpride. Ann Psychiatr 3: 298-305
17. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale: a procedure for measuring overall severity of psychiatric disorder. Arch Gen Psychiatry 33:766-771
18. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 50:448-455
19. Gerlach J (1991) New antipsychotics: Classification, efficacy and adverse effects. Schizophr Bull 17:289-309
20. 2 receptor antagonist, in drug-naive cebus monkeys. J Psychopharmacol 7:355-364
21. 1 receptor antagonist. Lancet 337:854-855
22. Jörgensen A (1980) Pharmacokinetic studies in volunteers of intravenuous and oral cis(Z)-flupenthixol and intramuscular cis(Z)-flupenthixol decanoate in viscoleo. Eur J Clin Pharmacol 18:355-360
23. Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848-851
24. Karle J, Clemnesen L, Hansen L, Andersen M, Andersen J, Fensbo C, Sloth-Niesen M, Skrumsager EB, Lublin H, Gerlach J (1995) NNC 01-0678 a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121: 328-329
25. 1-receptor antagonist SCH 39166 in schizophrenia. Neuropsychopharmacology 10:32
26. Leysen JE, Janssen PME, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112:40-54
27. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K (1987) The UKU side effects rating scale. Scale for the registration of unwanted effects of psychotropics. Acta Psychiatr Scand 76 [Suppl 334]:81-94
28. 3 receptors. Mol Pharmacol 43: 749-754
29. 1 receptor antagonist. Eur J Pharmacol 202:133-134
30. 2 and serotonirn pKi values. J Pharmacol Exp Ther 251:238-246
31. Möller HJ, Boyer P, Fleurot O, Rein W, and the PROD-ASLP Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132:396-401
32. Overall JK, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
33. Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130-133
34. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82
35. Pichot P, Boyer P (1988) Etude multicentrique controlée en double insu. Amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus. Ann Psychiatr 3:326-332
36. Pocock SJ (1983) Clinical trials. A practical approach. Wiley, Chichester, pp 123-141
37. Richelson E, Nelson A (1984) Antagonism by neurolcptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197-204
38. Scottish Schizophrenia Research Group (1987) The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 150:334-338
39. Seeman P, Chau-Wong LT, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
40. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86:10156-10160
41. Simpson G, Angus JA (1979) A rating scale for extrapyramidal side effects. Acta Psychiatr Stand 70 [Suppl 212]:11-19
42. 3) as a target for neuroleptics. Nature 347:146-151
43. 1. Nature 350:614-619
44. 4 receptor with a high affinity for the antipsychotic clozapine. Nature 350:610-614
45. 5 dopamine receptor mechanisms in relation to antipsychotic activity. In. Barnes TRE (ed) Antipsychotic drugs and their side effects. Academic Press, London, pp 65-85
46. Wetzel H, Benkert O (1993) New psychotropic drugs for acute treatment of schizophrenia. In: Costa e Silva JA , Nadelson CC (eds) International Review of Psychiatry, vol 1. American Psychiatric Press, Washington, DC, pp 185-229
47. Wetzel H, Wiedemann K, Holsboer F, Benkert O (1991) Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 103:280-283